Immix Biopharma, Inc. stock is down -19.32% since 30 days ago. The next earnings date is Mar 25, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 0% of the previous 2 February’s closed higher than January.
Immix Biopharma, Inc. engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination clinical trial in solid tumors of IMx-110 and anti-PD-1 Tislelizumab.
Unlock Exclusive Market Insights! Receive timely updates on market developments. Sign up & stay informed!